CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
138.58
0.58%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.24
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Dexcom Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 139.39
Open* 139.67
1-Year Change* 20.54%
Day's Range* 138.57 - 140.39
52 wk Range 74.75-139.55
Average Volume (10 days) 2.76M
Average Volume (3 months) 76.54M
Market Cap 49.24B
P/E Ratio 144.33
Shares Outstanding 386.37M
Revenue 3.40B
EPS 0.88
Dividend (Yield %) N/A
Beta 1.20
Next Earnings Date Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 139.39 -1.75 -1.24% 141.14 141.42 137.86
Mar 26, 2024 139.81 -0.77 -0.55% 140.58 141.52 138.33
Mar 25, 2024 140.00 6.72 5.04% 133.28 140.67 133.12
Mar 22, 2024 133.08 0.59 0.45% 132.49 134.20 131.11
Mar 21, 2024 133.31 1.02 0.77% 132.29 136.14 132.29
Mar 20, 2024 132.40 -1.30 -0.97% 133.70 135.19 131.16
Mar 19, 2024 134.06 0.37 0.28% 133.69 134.25 131.36
Mar 18, 2024 134.61 3.95 3.02% 130.66 135.48 130.66
Mar 15, 2024 130.39 0.85 0.66% 129.54 131.51 128.45
Mar 14, 2024 129.44 -2.34 -1.78% 131.78 132.39 128.63
Mar 13, 2024 131.56 -3.90 -2.88% 135.46 137.23 131.42
Mar 12, 2024 135.27 3.33 2.52% 131.94 136.62 130.19
Mar 11, 2024 132.95 -1.21 -0.90% 134.16 135.97 132.93
Mar 8, 2024 135.17 1.59 1.19% 133.58 136.09 132.02
Mar 7, 2024 133.12 -2.18 -1.61% 135.30 137.66 132.15
Mar 6, 2024 133.61 7.66 6.08% 125.95 133.81 123.94
Mar 5, 2024 121.71 -0.72 -0.59% 122.43 123.48 120.69
Mar 4, 2024 122.23 0.70 0.58% 121.53 124.12 120.42
Mar 1, 2024 121.69 7.68 6.74% 114.01 122.14 113.36
Feb 29, 2024 114.94 0.29 0.25% 114.65 115.43 113.87

DexCom, Inc. Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Dexcom Inc Earnings Release
Q1 2024 Dexcom Inc Earnings Release

Forecast

-

Previous

-
Friday, May 17, 2024

Time (UTC)

21:00

Country

US

Event

DexCom Inc Annual Shareholders Meeting
DexCom Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 2909.8 2448.5 1926.7 1476 1031.6
Revenue 2909.8 2448.5 1926.7 1476 1031.6
Cost of Revenue, Total 1012.8 739.9 622.2 530.4 367.7
Gross Profit 1897 1708.6 1304.5 945.6 663.9
Total Operating Expense 2518.6 2182.8 1627.2 1333.7 1217.9
Selling/General/Admin. Expenses, Total 1000.2 806.8 618.2 515.7 432.8
Research & Development 484.2 604.2 359.9 273.5 417.4
Operating Income 391.2 265.7 299.5 142.3 -186.3
Interest Income (Expense), Net Non-Operating -0.4 -8.9 -1.6 -38.1 59.8
Other, Net
Net Income Before Taxes 390.8 256.8 297.9 104.2 -126.5
Net Income After Taxes 341.2 216.9 549.7 101.1 -127.5
Net Income Before Extra. Items 341.2 216.9 549.7 101.1 -127.5
Net Income 341.2 216.9 549.7 101.1 -127.1
Income Available to Common Excl. Extra. Items 341.2 216.9 549.7 101.1 -127.5
Income Available to Common Incl. Extra. Items 341.2 216.9 549.7 101.1 -127.1
Diluted Net Income 341.2 216.9 549.7 101.1 -127.1
Diluted Weighted Average Shares 427.5 428.8 420.4 369.2 352.8
Diluted EPS Excluding Extraordinary Items 0.79813 0.50583 1.30756 0.27384 -0.36139
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 0.83101 0.60964 1.36632 0.33848 -0.35145
Total Extraordinary Items 0 0.4
Unusual Expense (Income) 13.9 28.2 24.4 14.1
Depreciation / Amortization 7.5 3.7 2.5
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 975 871.3 741.5 815.2 769.6
Revenue 975 871.3 741.5 815.2 769.6
Cost of Revenue, Total 351.7 324.9 278.9 260 275.4
Gross Profit 623.3 546.4 462.6 555.2 494.2
Total Operating Expense 769.5 743.2 694.3 689.8 622.1
Selling/General/Admin. Expenses, Total 284.7 297.3 294.6 297.8 234.6
Research & Development 131.4 119.3 119 116.3 110.3
Operating Income 205.5 128.1 47.2 125.4 147.5
Interest Income (Expense), Net Non-Operating 1 31.2 17.3 7.8 -1.3
Net Income Before Taxes 240.4 159.3 64.5 133.2 146.2
Net Income After Taxes 120.7 115.9 48.6 91.8 101.2
Net Income Before Extra. Items 120.7 115.9 48.6 91.8 101.2
Net Income 120.7 115.9 48.6 91.8 101.2
Income Available to Common Excl. Extra. Items 120.7 115.9 48.6 91.8 101.2
Income Available to Common Incl. Extra. Items 120.7 115.9 48.6 91.8 101.2
Diluted Net Income 120.7 115.9 48.6 91.8 101.2
Diluted Weighted Average Shares 426.8 431.5 418.5 426 425.8
Diluted EPS Excluding Extraordinary Items 0.2828 0.2686 0.11613 0.21549 0.23767
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.2828 0.2686 0.11613 0.23798 0.23767
Unusual Expense (Income) 13.9
Depreciation / Amortization 1.7 1.7 1.8 1.8 1.8
Other, Net 33.9
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 3668.8 3684.4 3424.8 1969.4 1699.5
Cash and Short Term Investments 2456.2 2731.2 2707.7 1533.3 1385.6
Cash & Equivalents 642.3 1052.6 817.6 446.2 1137
Short Term Investments 1813.9 1678.6 1890.1 1087.1 248.6
Total Receivables, Net 713.3 514.3 428.5 286.3 226.7
Accounts Receivable - Trade, Net 713.3 514.3 428.5 286.3 226.7
Total Inventory 306.7 357.3 234.7 119.8 70.7
Prepaid Expenses 192.6 81.6 53.9 30 16.5
Total Assets 5391.7 4933.3 4290.5 2395 1916
Property/Plant/Equipment, Total - Net 1135.6 889.9 608.6 392.8 183.1
Property/Plant/Equipment, Total - Gross 1498.8 1121.4 762.8 497.8 262.9
Accumulated Depreciation, Total -363.2 -231.5 -154.2 -105 -79.8
Goodwill, Net 25.7 26.5 19.3 18.6 18.7
Intangibles, Net 173.3 31.5
Other Long Term Assets, Total 388.3 301 237.8 14.2 14.7
Total Current Liabilities 1839.3 720.8 614.1 360.2 222.4
Accounts Payable 237.9 189.4 163.3 102.3 75.5
Accrued Expenses 814.5 514.3 439.8 255.6 144
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 776.8 8.8 0.6
Other Current Liabilities, Total 10.1 17.1 2.2 1.7 2.9
Total Liabilities 3259.9 2891.2 2464 1512.4 1252.7
Total Long Term Debt 1257.3 2038.8 1721.2 1074.1 1017.6
Long Term Debt 1197.7 1981.8 1667.2 1059.7 1010.3
Capital Lease Obligations 59.6 57 54 14.4 7.3
Other Liabilities, Total 158.4 125.7 128.7 78.1 12.7
Total Equity 2131.8 2042.1 1826.5 882.6 663.3
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.4 0.1 0.1 0.1 0.1
Additional Paid-In Capital 2258.1 2109 2125.3 1675.9 1560.6
Retained Earnings (Accumulated Deficit) 479.9 138.7 -202.1 -695.7 -798.9
Other Equity, Total -11.6 0.5 3.2 2.3 1.5
Total Liabilities & Shareholders’ Equity 5391.7 4933.3 4290.5 2395 1916
Total Common Shares Outstanding 386.3 388 384.4 366.4 360
Treasury Stock - Common -595 -206.2 -100 -100 -100
Deferred Income Tax 4.9 5.9
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 4698.4 5002.9 3767.4 3668.8 3398.5
Cash and Short Term Investments 3240.3 3636.2 2567 2456.2 2371.9
Cash & Equivalents 643.7 1194.9 623.2 642.3 698.1
Short Term Investments 2596.6 2441.3 1943.8 1813.9 1673.8
Total Receivables, Net 785.7 755.6 652.5 713.3 564.1
Accounts Receivable - Trade, Net 785.7 750.6 636.8 713.3 564.1
Total Inventory 498.6 421.1 366 306.7 311
Prepaid Expenses 173.8 190 181.9 192.6 151.5
Total Assets 6596.2 6820.7 5515.9 5391.7 4899.2
Property/Plant/Equipment, Total - Net 1152.3 1153.9 1153.5 1135.6 1075.6
Property/Plant/Equipment, Total - Gross 1618.6 1582.2 1548 1498.8 1414.1
Accumulated Depreciation, Total -466.3 -428.3 -394.5 -363.2 -338.5
Goodwill, Net 25.3 25.8 25.7 25.7 24.7
Other Long Term Assets, Total 575.7 483.9 405.7 388.3 376
Total Current Liabilities 1678.6 2069.7 1865 1839.3 900.5
Accounts Payable 242.4 269.1 266.2 237.9 198.1
Accrued Expenses 1303 1017.8 816 818.7 699.7
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 9 9 9.6 10.1 2.7
Total Liabilities 4328.3 4720.3 3282.9 3259.9 3074.7
Total Long Term Debt 2490.3 2489.1 1257.7 1257.3 2029.2
Long Term Debt 2432.4 2430.6 1198.5 1197.7 1968.8
Capital Lease Obligations 57.9 58.5 59.2 59.6 60.4
Other Liabilities, Total 154.8 156.7 155.4 158.4 139.7
Total Equity 2267.9 2100.4 2233 2131.8 1824.5
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.4 0.4 0.4 0.4 0.4
Additional Paid-In Capital 3618 2269 2305.6 2258.1 2072.1
Retained Earnings (Accumulated Deficit) 765.1 644.4 528.5 479.9 388.1
Treasury Stock - Common -2080 -784.1 -595 -595 -595
Other Equity, Total -35.6 -29.3 -6.5 -11.6 -41.1
Total Liabilities & Shareholders’ Equity 6596.2 6820.7 5515.9 5391.7 4899.2
Total Common Shares Outstanding 386.4 386.1 387.6 386.3 386.2
Intangibles, Net 144.5 154.2 163.6 173.3 24.4
Deferred Income Tax 4.6 4.8 4.8 4.9 5.3
Current Port. of LT Debt/Capital Leases 124.2 773.8 773.2 772.6
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 341.2 154.7 493.6 101.1 -127.1
Cash From Operating Activities 669.5 442.5 475.6 314.5 123.2
Cash From Operating Activities 155.9 102 67.1 48.7 29.1
Non-Cash Items 167.3 322.7 213 158.6 262.1
Cash Taxes Paid 114.2 16.8 3.6 4.8 2.3
Cash Interest Paid 12.2 11.6 10.6 10.4 3.6
Changes in Working Capital 26.7 -132 -20.8 6.1 -40.9
Cash From Investing Activities -521.5 -216.1 -1018 -1015.2 -139.8
Capital Expenditures -364.8 -389.2 -199 -180 -67.1
Other Investing Cash Flow Items, Total -156.7 173.1 -819 -835.2 -72.7
Cash From Financing Activities -552.5 10.4 912.1 10.7 710.4
Issuance (Retirement) of Stock, Net -535.2 20.3 15.3 11.9 94.6
Issuance (Retirement) of Debt, Net 0 0 906.2 0 617.7
Net Change in Cash -410.3 235.4 371.8 -690.7 695.6
Foreign Exchange Effects -5.8 -1.4 2.1 -0.7 1.8
Financing Cash Flow Items -17.3 -9.9 -9.4 -1.2 -1.9
Deferred Taxes -21.6 -4.9 -277.3
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 48.6 341.2 249.4 148.2 97.3
Cash From Operating Activities 155.4 669.5 537 243.8 71
Cash From Operating Activities 41.6 155.9 119.6 80.4 36.8
Deferred Taxes -9.3 -21.6 -53.6 -19.8 0.1
Non-Cash Items 23 167.3 128.9 80.7 34.3
Changes in Working Capital 51.5 26.7 92.7 -45.7 -97.5
Cash From Investing Activities -186.7 -521.5 -327.4 -556.7 -411.8
Capital Expenditures -74.7 -364.8 -301.3 -193.1 -101.6
Other Investing Cash Flow Items, Total -112 -156.7 -26.1 -363.6 -310.2
Cash From Financing Activities 11.2 -552.5 -551.5 1 5.3
Financing Cash Flow Items -1.1 -17.3 -16.3 -9.1 -4.8
Issuance (Retirement) of Stock, Net 12.3 -535.2 -535.2 10.1 10.1
Foreign Exchange Effects 1.1 -5.8 -12.6 -5.3 -1
Net Change in Cash -19 -410.3 -354.5 -317.2 -336.5
Issuance (Retirement) of Debt, Net 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

DexCom Company profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry: Medical Equipment, Supplies & Distribution (NEC)

6340 Sequence Dr
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,561.25 Price
+1.380% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.63 Price
+1.650% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading